Blueprint Medicines Stock Analysis (NASDAQ:BPMC)

Add to My Stocks
$39.9 $0.29 (0.73%) BPMC stock closing price May 22, 2017 (Closing)
Watch Robo Advisor Video of BPMC Stock Analysis
Blueprint Medicines
Updated on : May 22, 2017
previous close
BPMC 39.9 (0%)
S&P 500 2394 (0%)
Closing Price On: May 22, 2017
stock rating
RATING: ★★★★★★★★★★ (0/5)
Industry :
Medical-Biomed-Genetics
Sector :
Medical
5 Quarter Revenue
Revenue Growth
2017-Q1
$million
%
YOY GROWTH
Compared to the industry
Operating Profit
Operating Margin:
-319.4%
Sector Average:
1.1%
5 Quarter Net Profit
Net Margins
2017-Q1
%
LTM Margin
Debt/Equity Ratio
Debt:
6.5M
Debt/Equity Ratio:
 0.03
Compared to the industry
Cash Flow
Operating cash flow:
-$31.1M
Net Income:
-$28M
PROS      CONS
Low Debt Burden
Operating Margins
Net Margins
ROE
FCF Margin
PE Valuation
PS Valuation
Rating: ★★★★★★★★★★ (0/5)
Relative Valuation
PE: N/A
BPMC PS :
49.5
Industry PS :
4.6
Sector:   Medical.   *PE adjusted for one time items.
Other Metrics
Return on Equity:
-57.3%
Free Cash Flow Margin:
-535.8%
Double Tap To Exit Full Screen
0:00
/

Blueprint Medicines Analysis Video

12 5 2

View Blueprint Medicines stock analysis video. This is our BPMC analyst opinion covering the buy and sell arguments for BPMC stock.

Blueprint Medicines Corp Stock Rating (1.9/5)

Our Blueprint Medicines stock opinion is based on fundamentals of the company. This Blueprint Medicines stock analysis is based on latest Q1 earnings for 2017. The stock price analysis takes into account a company's valuation metrics.

Should you buy BPMC stock?

  • Blueprint Medicines has a lower debt burden than its peers in the Medical sector, with a debt/equity ratio of  0.03.

Should you sell BPMC stock?

  • Over the last twelve months, Blueprint Medicines posted an average operating loss margin of -319.4%.
  • Over the last 12 months, Blueprint Medicines had an average Net loss of -317.5%.
  • PE ratio is meaningless for BPMC stock as the company has losses.
  • The company is trading at a price to sales multiple of 49.5, which is higher in comparison to the Medical-Biomed-Genetics industry average of 4.6, making BPMC stock expensive.
  • Blueprint Medicines has a negative return on equity of -57.3%. This indicates that the firm is inefficient at generating profits.
  • Blueprint Medicines has a negative FCF (Free Cash Flow) margin of -535.8%.

Comments on this video and Blueprint Medicines stock